GOVERNMENT OF INDIA
MINISTRY OF RAILWAYS
(RAILWAY BOARD)

No. 2018/H/4/1/Drug/Vigilance **New Delhi, Dated: 22.03.2019**

General Manager(s),
All Indian Railways,
Including PUs & RDSO.

Sub: Monitoring of the rejected stores by Headquarters-system improvement-reg.

****

Arising out of a Joint-check conducted by CBI & Vigilance in a particular Division, samples of certain items/drugs were drawn and subjected to test by Central Drug Laboratory wherein some of the products were found to be non-conforming to the laid down standards. The said report was forwarded to the CMS of the Division by the Drug Control Authority with an advice for the following action:-

a) To stop further distribution/sale of the above item.
b) To furnish balance quantity in stock of the same as well as their purchase particulars also with relevant records.
c) To get the item back which were issued to other units but not consumed by them till date.

However, the CMS did not forward the report to the Sr. DMO (Stores) for about 8 months of the receipt of the test report. Further, though the Sr. DMO issued a Show-Cause notice to the firm as to why the firm should not be blacklisted, the supplier firm did not submit any reply. In the process, the drug/pharmaceuticals product which was declared to be of sub-standards quality continued to be used in the hospitals.

The above situation has been viewed seriously. All the zones/PUs are desired to ensure that the information regarding various rejected Stores is monitored at Headquarter level to ensure their timely replacement/recovery of cost and consequential action against the firms, wherever warranted, in terms of laid down rules. Further, consumption of the product would also be stopped immediately on receipt of adverse report.

This has the approval of Director General (RHS).

(R.S. Shukla)
Joint Director (Health)
Railway Board